TOP > 外国特許検索 > CYCLIC PEPTIDE COMPOUND OR PHARMACOLOGICALLY ACCEPTABLE SALT THEREOF AND METHOD FOR PRODUCING SAME

CYCLIC PEPTIDE COMPOUND OR PHARMACOLOGICALLY ACCEPTABLE SALT THEREOF AND METHOD FOR PRODUCING SAME UPDATE 新技術説明会

外国特許コード F120006849
整理番号 S2012-0295-N0
掲載日 2012年9月19日
出願国 世界知的所有権機関(WIPO)
国際出願番号 2011JP065521
国際公開番号 WO 2012005313
国際出願日 平成23年7月6日(2011.7.6)
国際公開日 平成24年1月12日(2012.1.12)
優先権データ
  • 特願2010-155576 (2010.7.8) JP
発明の名称 (英語) CYCLIC PEPTIDE COMPOUND OR PHARMACOLOGICALLY ACCEPTABLE SALT THEREOF AND METHOD FOR PRODUCING SAME UPDATE 新技術説明会
発明の概要(英語) Provided are a cyclic peptide compound, which can inhibit parakeratosis of the skin, or a pharmacologically acceptable salt thereof and a method for producing the same.
従来技術、競合技術の概要(英語) BACKGROUND ART
The epidermis of a human, in order from the bottom, the base layer and the stratum corneum and stratum spinosum layer made of the granule layer. In human normal skin, the stratum corneum layer, barrier development of the function, or physical stimulus and protecting the skin from chemical stimulation.
Normal skin is, usually, in the period between 28 to turnover. In the turn over of normal skin, the keratinocytes are pushed up from the stratum corneum to the granular layer. At this time, the de-nucleated occurs by keratinocyte differentiation is lost and the nucleated cells, mature stratum corneum is formed. However, too fast turnover or the like, in the keratinocytes of the final stage of differentiation, de-nucleated does not occur, and generate the stratum corneum is not full, the barrier function is significantly reduced. Such non-full-width same way as in the state, applied on the skin of oleic acid (non-patent document 1) also be caused by.
On the other hand, is , involved in the regulation of morphogenesis of epithelial tissue of one of the factors that are thought to be 1 (non-patent document 2-5). In addition, by knocking out of the , results in a decrease in the crystallization-inducing cancer in mice have been reported (for example, see non-patent document 6).
Wherein in order to control the morphogenesis of epithelial tissue, epithelial tissue in that the function of promoting the formation inhibits the action of the oligopeptide is proposed (for example, see Patent Document 1 and 2).
However, epithelial tissue morphogenesis promoting action with respect to the inhibitory action of oligopeptide, to control the morphogenesis of epithelial tissue will be insufficient, caused by skin epithelial cells such as embodiment, occurrence of abnormality of the differentiation and the like can be suppressed with high efficiency has been desired in the further useful compounds.
  • 出願人(英語)
  • ※2012年7月以前掲載分については米国以外のすべての指定国
  • KWANSEI GAKUIN EDUCATIONAL FOUNDATION
  • 発明者(英語)
  • HIRAI YOHEI
  • Okuyo Yoji
国際特許分類(IPC)
指定国 National States: AE AG AL AM AO AT AU AZ BA BB BG BH BR BW BY BZ CA CH CL CN CO CR CU CZ DE DK DM DO DZ EC EE EG ES FI GB GD GE GH GM GT HN HR HU ID IL IN IS JP KE KG KM KN KP KR KZ LA LC LK LR LS LT LU LY MA MD ME MG MK MN MW MX MY MZ NA NG NI NO NZ OM PE PG PH PL PT RO RS RU SC SD SE SG SK SL SM ST SV SY TH TJ TM TN TR TT TZ UA UG US UZ VC VN ZA ZM ZW
ARIPO: BW GH GM KE LR LS MW MZ NA SD SL SZ TZ UG ZM ZW
EAPO: AM AZ BY KG KZ MD RU TJ TM
EPO: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
OAPI: BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG
ライセンスをご希望の方、特許の内容に興味を持たれた方は、下記「問合せ先」までお問い合わせください。

PAGE TOP

close
close
close
close
close
close